Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Jan 12, 2015
Sangamo BioSciences To Highlight 2015 Catalysts And Advancement Of ZFP Therapeutic Programs At The 33rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2015
Sangamo BioSciences Announces In-Licensing Of mRNA Delivery Technology And Expansion Of Therapeutic Pipeline Opportunities For Sangamo's In Vivo ZFN Genome-Editing Platform


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
13.79
Change:
+ 0.07
Day High:
14.03
Day Low:
13.36
Volume:
553,700
4:00 PM ET on Jan 27, 2015

Shareholder Tools